Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 6/20 | 0.53 |
| ▸ | CDK1 | P06493 | 3/20 | 0.53 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.53 |
| ▸ | CDK2 | P24941 | 2/20 | 0.53 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | MGMT | P16455 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | CDC7 | O00311 | 1/20 | 0.47 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.47 |
| ▸ | PNP | P00491 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18605740 | 0.99 | PIN1 (0.52) | PIN1CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL17186533 | 0.81 | SMN1; SMN2 (0.42) | PIN1CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL27775483 | 0.80 | CDK1 (0.43) | PIN1CDK1CCNB1CCNA2CDK2 | |
| Hydrochloric Acid SCHEMBL18605766 | 0.80 | SMN1; SMN2 (0.42) | PIN1CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL8995752 | 0.80 | PNP (0.41) | PIN1CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL17186555 | 0.79 | PIK3CA (0.40) | CDK2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL17186403 | 0.79 | PNP (0.40) | PIN1CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL20970002 | 0.79 | PIN1 (0.39) | PIN1CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL8583450 | 0.79 | CDK1 (0.49) | PIN1CDK1CCNB1CCNA2CDK2 | |
| Hydrochloric Acid SCHEMBL17186643 | 0.78 | PIK3CA (0.39) | CDK2CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | IMMUNOMET THERAPEUTICS INC. (US) | 2017-03-16 | — | — | US | claimed |
| EP-3131877-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | Immunomet Therapeutics Inc. (US) | 2017-02-22 | — | — | EP | claimed |
| WO-2015160220-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | HANALL BIOPHARMA CO., LTD. (KR) | 2015-10-22 | — | — | WO | claimed |
| US-5525726-A | Process for the preparation of an antiviral agent | E. R. SQUIBB & SONS, INC. (US) | 1996-06-11 | — | — | US | claimed |
| US-5516903-A | Process for preparing [IR-(1α,2β-3α)]-2-amino-9-[2,3-bis(hydroxymethyl)cyclobutyl]-1,9-dihydro-6H-purin-6-one | E. R. SQUIBB & SONS, INC. (US) | 1996-05-14 | — | — | US | claimed |
| CN-117924514-B | Probe system for detecting cholesterol and application thereof | 重庆医科大学 | 2025-04-04 | — | — | CN | disclosed |
| CN-117924514-A | Probe system for detecting cholesterol and application thereof | 重庆医科大学 | 2024-04-26 | — | — | CN | disclosed |
| EP-3131877-B1 | BIGUANIDE COMPOUNDS | IMMUNOMET THERAPEUTICS INC (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | IMMUNOMET THERAPEUTICS INC. (US) | 2017-03-16 | — | — | US | disclosed |
| EP-3131877-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | Immunomet Therapeutics Inc. (US) | 2017-02-22 | — | — | EP | disclosed |
| WO-2015160220-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | HANALL BIOPHARMA CO., LTD. (KR) | 2015-10-22 | — | — | WO | disclosed |
| US-6353122-B1 | IN CYCLOHEXANONE WITH POTASSIUM PEROXYMONOSULFATE AND SUBSEQUENT REARRANGEMENT TO PROVIDE THE CORRESPONDING CYCLOBUTANONE | BRISTOL-MYERS SQUIBB COMPANY | 2002-03-05 | — | — | US | disclosed |
| CN-1082025-A | 2 of two protections, the preparation method of 3-methylol cyclobutanol | SQUIBB & SONS INC (US) | 1994-02-16 | — | — | CN | disclosed |
| EP-0572209-A2 | Process for preparing diprotected 2,3-hydroxymethyl cyclobutanol | E.R. SQUIBB & SONS, INC. (US) | 1993-12-01 | — | — | EP | disclosed |
| US-5237095-A | Process for the preparation of an antiviral agent | E. R. SQUIBB & SONS, INC. (US) | 1993-08-17 | — | — | US | disclosed |
| US-5237096-A | Process for the preparation of an antiviral agent | E. R. SQUIBB & SONS, INC. (US) | 1993-08-17 | — | — | US | disclosed |
| US-5233086-A | Intermediates for the preparation of an antiviral agent | E. R. SQUIBB & SONS, INC. (US) | 1993-08-03 | — | — | US | disclosed |
| US-5218142-A | Process for the preparation of an antiviral agent | E. R. SQUIBB & SONS, INC. (US) | 1993-06-08 | — | — | US | disclosed |
| EP-0535448-A2 | Process and intermediates for the preparation of an antiviral agent containing a cyclobutyl group | E.R. SQUIBB & SONS, INC. (US) | 1993-04-07 | — | — | EP | disclosed |
| US-5185463-A | PROCESS FOR THE PREPARATION OF AN ANTIVIRAL AGENT | E. R. SQUIBB & SONS, INC. (US) | 1993-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | PC, TFAM, PCK2 | PIN1 1818/4885CDK1 592/4885CCNB1 3063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.